Toronto Dominion Bank grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 19.0% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 472,577 shares of the biopharmaceutical company’s stock after purchasing an additional 75,364 shares during the quarter. Toronto Dominion Bank’s holdings in Gilead Sciences were worth $33,445,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Seizert Capital Partners LLC grew its position in shares of Gilead Sciences by 4.6% in the first quarter. Seizert Capital Partners LLC now owns 632,574 shares of the biopharmaceutical company’s stock valued at $42,964,000 after purchasing an additional 27,547 shares during the last quarter. Investment Centers of America Inc. grew its position in shares of Gilead Sciences by 7.2% in the first quarter. Investment Centers of America Inc. now owns 29,064 shares of the biopharmaceutical company’s stock valued at $1,979,000 after purchasing an additional 1,958 shares during the last quarter. Northern Trust Corp grew its position in shares of Gilead Sciences by 0.7% in the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares during the last quarter. Fagan Associates Inc. grew its position in shares of Gilead Sciences by 2.6% in the second quarter. Fagan Associates Inc. now owns 33,075 shares of the biopharmaceutical company’s stock valued at $2,341,000 after purchasing an additional 845 shares during the last quarter. Finally, Dai Ichi Life Insurance Company Ltd grew its position in shares of Gilead Sciences by 7.6% in the second quarter. Dai Ichi Life Insurance Company Ltd now owns 160,025 shares of the biopharmaceutical company’s stock valued at $11,327,000 after purchasing an additional 11,299 shares during the last quarter. 76.23% of the stock is currently owned by institutional investors.

Several equities research analysts recently issued reports on GILD shares. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Thursday, September 7th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Monday, September 11th. Vetr cut Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price target for the company. in a research note on Monday, September 4th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a $83.00 price target (up from $77.00) on shares of Gilead Sciences in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $85.11.

In other news, EVP Gregg H. Alton sold 25,000 shares of the stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total value of $2,066,250.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Gregg H. Alton sold 15,000 shares of the stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.64, for a total value of $1,119,600.00. Following the completion of the sale, the executive vice president now owns 70,988 shares of the company’s stock, valued at $5,298,544.32. The disclosure for this sale can be found here. Insiders sold a total of 494,999 shares of company stock valued at $37,404,139 over the last quarter. 1.30% of the stock is owned by corporate insiders.

Gilead Sciences, Inc. (GILD) opened at $76.58 on Thursday. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a market capitalization of $99,119.69, a price-to-earnings ratio of 7.92, a PEG ratio of -1.27 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. During the same period in the prior year, the company earned $2.75 EPS. Gilead Sciences’s revenue was down 13.2% compared to the same quarter last year. sell-side analysts predict that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Stockholders of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.72%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s payout ratio is 23.69%.

TRADEMARK VIOLATION NOTICE: “Toronto Dominion Bank Boosts Stake in Gilead Sciences, Inc. (GILD)” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/12/14/toronto-dominion-bank-boosts-stake-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related stocks with our FREE daily email newsletter.